View:
CUMBERLAND PHARMACEUTICALS, INC.
1600 West End Avenue, Suite 1300
Nashville, Tennessee 37203
December 21, 2023
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F. Street, N.E.
Washington, D.C. 20549
Re: Cumberland Pharmaceuticals, Inc.
Registration Statement on Form S-3
File Number 333-276052
REQUEST FOR ACCELERATION OF EFFECTIVENESS
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Cumberland Pharmaceuticals, Inc. (the “Registrant”) hereby requests acceleration of the registration statement on Form S-3 (File No. 333-276052) to 4:00 p.m., Eastern Time, on December 26, 2023 or as soon as practicable thereafter.
In connection with this request, the Registrant acknowledges that:
•should the Securities and Exchange Commission (the “Commission”) or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
•the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Registrant from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
•the Registrant may not assert this action as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Please contact our legal counsel, Tonya Mitchem Grindon, of Baker, Donelson, Bearman, Caldwell & Berkowitz, PC, at (615) 726-5607, if you have any questions concerning this request.
Very truly yours,
Cumberland Pharmaceuticals, Inc.
By: /s/ John Hamm
Name: John Hamm
Title: Chief Financial Officer